Presented at #ASCO25: The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer. Full BREAKWATER phase 3 trial results:

Adding to growing evidence of #AI -based CT scan muscle analysis in cancer. Pts with mCRC receiving 1L FOLFOX or FOLFIRI with low skeletal muscle index had higher rates of ≥G3 neutropenia. journals.sagepub.com/eprint/RSAKM... #CancerCachexia @ryannipp.bsky.social @pallonccop.bsky.social

SWOG 2210 is open for #prostatecancer patients w/ BRCA1 or BRCA2. Fascinating to see BRCA’s role in other cancers. Hoping we see biomarkers unlock clues in RCC soon. #GUonc #oncsky #cansky

So thrilled to be joined by @missmeganel.bsky.social to discuss her amazing essay “Tamales” in our latest @ascocancer.bsky.social #CancerStories podcast! Listen to how patients invite their doctors into their culture and their world. 🎗️♥️🇲🇽 ascopubs.org/do/tamales-cel…

"If palliative care clinicians walk the line between security and vulnerability, then they must expect to misstep sometimes." This Viewpoint explores why palliative care clinicians may be at increased risk for dismissal. #MedSky https://ja.ma/42bomND

Clinician researchers should just remove the work "trend" from your vocabulary. Seriously! 😜 If what you are indicating by using that word is actually important, you will be able to find another way to describe it. I promise.

A brief plea to call a spade a spade (or more specifically, call a phase 1 a phase 1; a phase 2 a phase 2; a phase 3 a phase 3). www.europeanurology.com/article/S030...

Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Resilience and the Fallacy of “One Size Fits All.” www.nejm.org/doi/abs/10.1... @nejm.org @harvardmed.bsky.social @danafarber.bsky.social #PallOnc #GeriOnc #PalliativeCare

@fumikochino.bsky.social published in @ascocancer.bsky.social this important #pallonc study #Fintox 💰 is direct costs (e.g., copays) ➕ indirect costs (e.g., lost income) ➡️: ⬆️stress and skipping #cancer meds. 4 step #COST frame work ⬆️🗣️ 🔗: ascopubs.org/doi/10.1200/...

At some point the US will need to consider value when approving drugs (or at least deciding if we are going to pay for them).

re: cancer label for lo-risk cancer: either a) relabel "but ensure patients understand [need for] monitoring" or b) don't relabel "but ensure patients understand lesions are unlikely to cause problems, so surveillance is appropriate." We know a) works better then b). jamanetwork.com/journals/jam...

Cancer affects all in some way. Change is coming after too brief a period of great leadership by Dr. Kimryn Rathmell. Whatever happens it is an honor to express a vision for the field of cancer research & innovation in oncology. Research on causes & cures brings hope for patients.

I, too, have been surprised by the rise of "tornado plots" to plot clinical trial AEs at our conferences! 100% agree with ⬆️ this simple data vis change to improve interpretability of AEs.

#ESMOImmuno24 Proffered paper🔥 Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social - no PFS/OS benefit - g3+TRAE 57%, 54%, 49% - concerning pneumonitis signal Concurrent RT+IO - going going gone @oncoalert.bsky.social #LCSM #Medsky #Oncsky

1/4 @swog.org lung cancer trial, PRAGMATICA, closes early! This randomized trial enrolled 800 volunteers w stage 3-4 lung cancer in 21 months (goal was 700 in 24m). Tested chemo vs ramicirumab/pembrolizumab. Not applicable to every trial, but...

Hot of the press from @proteuspros - an infographic explaining the value of PROs! Note - they need to start as parr of the clinical encounter to benefit patients and society. tinyurl.com/3m594fhk

Remote Symptom Monitoring of Patients With Advanced Lung #Cancer (The ProWide Study): A Randomized Controlled Trial. ascopubs.org/doi/10.1200/... @ascopost.bsky.social #LungCancer #PallOnc #SuppOnc

De-escalation discussion on Europa trial tag line - which would you prefer, 5 days of RT or 5 years of ET…. 🤔🤔 No-brainer?? Supported by BASO II trial longer term data #SABC24

This is great because patients hate endocrine therapy! However, we need to see recurrence data before adopting in the clinic. #BCSM #SABCS24

#SABCS24 #bcsm #OncSky #RadOnc #MedSky BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence) @oncoalert.bsky.social

Omission of Axillary surgery continues to build momentum Here in pts w/ cN0 T1-2 invasive breast cancer—omission is noninferior to SLNB w 6 years med f/u Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial www.nejm.org/doi/full/10.... #SABCS24 @oncoalert.bsky.social @nejm.org

Dr. Singh draws nice comparisons between SOUND and INSEMA. #SABCS24 @oncoalert.bsky.social @sabcs.bsky.social

It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt. 4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean 2% ⬆️ recurrence in pts with N0 dz 📌Magnitude of effect larger among premeno. 📌ER + AND ER neg @sabcs.bsky.social #SABCS24 @oncoalert.bsky.social

📌 PATINA: a Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + ET vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor-Positive (HR+)/HER-Positive Metastatic Breast Cancer #SABCS24 #day3 @oncoalert.bsky.social

Better together- very excited about this @swog.org @alliancenctn.org #CTIU collaboration 🤝

I never tire of seeing these progressively improved pediatric ALL survival curves, which represent one of the most remarkable achievements in all of medicine. Amazing to see even more improvement with bispecific antibody #immunotherapy presented in the #ASH24 Plenary session. #hematology #leukemia

5-year POLARIX F/U #ASH24 - 5-yr PFS better w/ polaRCHP: 65% v 59% - no difference in OS (7 yr F/U planned) - more LBCL deaths in RCHOP arm, polaRCHP arm w/ less subsequent tx - in underpowered subgroup analysis, polaRCHP PFS/OS better in ABC 6% PFS benefit enough for SOC? #lymsm

If there is only one thing you will read today - make it this one! So many lessons on how to care: -illuminate the personhood -understand life outside the hospital -practical compassion -sit with darkness tinyurl.com/4h2u476m

The evidence that social determinants impact health is overwhelming. Excellent viewpoint makes compelling call for fully integrating social determinants into the US Health research priorities. jamanetwork.com/journals/jam...

The annual risk of pancreatic cancer was 0.04% for BRCA1 carriers and 0.09% for BRCA2 carriers, with a cumulative incidence by age 80 of 2.2% and 2.7%, respectively. Risk factors included alcohol consumption and diabetes, with only two cases reporting a first-degree relative with pancreatic cancer.

⭐️Artificial intelligence-aided data mining of medical records for cancer detection and screening www.thelancet.com/journals/lan...

⭐️Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis www.thelancet.com/journals/lan...

and a 2nd paper from the terrific MASCC Survivorship Group, on AI in symptom monitoring ascopubs.org/doi/10.1200/...

Pleased to share a couple of papers (just out). First from Dr Julia Lai-Kwon, from her PhD work, focused on implementing ePROs to monitor side effects from immunotherapy ➡️Read more: rdcu.be/d2eY9

#Algorithmovigilance!

Automatic metastatic versus localized stage extraction from clinical trial publications just published in JCO CCI. Check it out today, and let us know your thoughts! ascopubs.org/doi/abs/10.1... @acochran12733.bsky.social @emiliemgunn.bsky.social

Adherence is such big issue and such a challenging problem solve - we found the same thing in breast cancer patients taking endocrine therapy @swog.org study #S1105- pubmed.ncbi.nlm.nih.gov/32369401/ Lots of work needed to improve outcomes in patients who need oral therapies!!

Text message reminders targeting patients who delay refilling their cardiovascular medications did not improve medication adherence based on pharmacy refill data or reduce clinical events at 12 months. ja.ma/4irtinM

Directory of all bsky starter packs blueskydirectory.com/starter-pack...

This paper prompted me to look up “channeling bias” Channeling bias often results from clinicians’ tendencies to prescribe certain treatments to patients with particular prognostic factors or risk levels

(I urge that everyone read this article's very good accompanying editorial - a mix of skepticism & optimism - as well) jamanetwork.com/journals/jam... @jama.com @sumantranji.bsky.social

A friend sent this article to me today. It feels like a good moment to remind us: the LLM outperformed physicians on STRUCTURED cases. Someday the AIs may perform better than us in the unstructured, messy, real-world patient encounter...but that day is not today.🩺🛟 jamanetwork.com/journals/jam...

Do systemic responses to ICI (eg irAEs) associate w outcomes? Nice use of existing basket studies by @pateloncology.bsky.social @eladsharonmd.bsky.social Razelle Kurzrock et al

Only a subset of patients respond to immunotherapy Why? Which ones? We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response. www.nature.com/articles/s41...

Might we implement hashtag cancer communities on Bluesky? They genuinely help stakeholders (esp patients) find info related to a specific cancer. This paper explains how #bcsm #btsm #lcsm and other cancer community hashtags evolved on Twitter. ascopubs.org/doi/pdfdirec...

Two AIs talking about our paper on phases of methodological research in biostatistics doi.org/10.1002/bimj..., created with minimum effort - fascinating and a bit fearsome notebooklm.google.com/notebook/85f...

One of my imaging workhorses in the NET clinic, the CT enterography (CTE). Nothing better to visualize small NETs in the ileum. This patient has at least 30 small lesions that have been stable over many years and monitored with annual CTE. 50% or more of sbNETs are multifocal.